BioTuesdays

Category - Feature

Feature

Oramed readies oral insulin study in U.S.

Oramed Pharmaceuticals (NASDAQ:ORMP) is awaiting a decision from the FDA, possibly later this week, to conduct a sub-study of the safety of its oral insulin candidate, ORMD-0801, before proceeding to a large, multi...

May 7, 2013
Feature

Vaxil trial validates vaccine technology

Results of a recent clinical trial of Vaxil Bio’s (TASE:VAXL) ImMucin cancer vaccine in patients with multiple myeloma has validated the company’s VaxHit technology by demonstrating safety and a strong immune response...

April 23, 2013
Feature

OnPoint’s Big-Data Equals Big Opportunity

OnPoint Medical Diagnostics (OTCQB:ONMD) is pioneering a “big-data” platform for delivering measurable, objective and automated quality assurance (QA) solutions for magnetic resonance imaging (MRI), with plans to...

April 16, 2013
Feature

DURECT awaiting Pfizer meeting with FDA on Remoxy

DURECT (NASDAQ:DRRX) has a lot riding on a meeting in late March between its marketing partner, Pfizer, and the FDA to discuss resubmitting a new drug application for its lead pain drug, Remoxy, as a tamper-resistant...

February 26, 2013
Feature

In conversation with Will Zerhouni

As CEO of closely held i3 Analytics, Will Zerhouni founded the company on the belief that data analytics should be for everyone in biopharma, not just major players with deep pockets. As a former associate at Covington...

February 5, 2013
Feature

Prima BioMed to get key CVac data in second half

After posting positive trends in interim data, Prima BioMed (ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034) is focusing on two final data readouts in the second half this year from a Phase 2b clinical trial of its CVac cancer...

January 29, 2013